Biotechnology Innovation Organization ✓

@IAmBiotech · Washington, DC · joined 15 Jan 2009

I Am Biotech is where biotech professionals and enthusiasts can come together and discuss the promise of biotech innovation. #Biotech

105 484Followers

5 583Following

37 982Posts total

6.4KViews on collected posts

Últimas publicaciones

Biotechnology Innovation Organization ✓@IAmBiotech4 Sep

State legislatures wrapped their 2026 sessions with continued activity on prescription drug affordability boards, 340B oversight, vaccine liability, and AI regulation. https://t.co/R0l0lQE1s4 chatted with BIO's Patrick Plues on what he's tracking heading into 2027: https://t.co/M 902 views · 1 likes · 0 reposts · 0 replies Open on X →

Biotechnology Innovation Organization ✓@IAmBiotech3 Sep

@IAmBiotech @GileadSciences Why don’t you just CURE HIV? Not enough money 💰 in for the @FDA 52 views · 1 likes · 0 reposts · 0 replies Open on X →

Biotechnology Innovation Organization ✓@IAmBiotech3 Sep

At #BIOPACE26, experts will examine what it means to usher in 21st century access and affordability, with patient-centric policies that reduce barriers, bureaucracy, and delays - so patients can get the treatment they need, when they need it. View the full agenda: https://t.co/Q 891 views · 2 likes · 0 reposts · 1 replies Open on X →

Biotechnology Innovation Organization ✓@IAmBiotech3 Sep

50 years of biotechnology - in 50 seconds: kicking off Sickle Cell Awareness Month Chris Rofidal, Senior Director, Health Policy and Pipeline Strategy at United Therapeutics Corporation, reflects on a milestone the industry once thought impossible: a highly curative gene https 1.1K views · 1 likes · 0 reposts · 0 replies Open on X →

Biotechnology Innovation Organization ✓@IAmBiotech2 Sep

Congratulations to @GileadSciences on FDA approval of Bixlenvo, a once-daily single-tablet HIV treatment for adults living with HIV. 2.2K views · 5 likes · 0 reposts · 1 replies Open on X →

Biotechnology Innovation Organization ✓@IAmBiotech2 Sep

FDA's PDUFA VIII commitment letter recommends new efficiencies while leaning into the existing strengths of a system that makes America the world leader in biotech. BIO's lead negotiator breaks down what's in it on https://t.co/R0l0lQE1s4: https://t.co/w8BKADS6eN https://t.co/Hhs 1.2K views · 1 likes · 0 reposts · 0 replies Open on X →

Frente a cuentas del mismo tamaño

6 publicaciones de los últimos 90 días, junto al rango de 100K–1M seguidores. por debajo de sus pares en alcance y en interacción.

Visualizaciones medianas1 009esta cuenta5 983mediana de 100K–1M

Alcance, %0.96%esta cuenta1.49%mediana de 100K–1M

Interacción, %0.22%esta cuenta0.93%mediana de 100K–1M

Métrica	Esta cuenta	Mediana de 100K–1M	Proporción
Visualizaciones medianas por publicación	1 009	5 983	0.17×
Alcance (visualizaciones ÷ seguidores)	0.96%	1.49%	0.64×
Tasa de interacción	0.22%	0.93%	0.24×

Otras cuentas de este rango → Comparar con otra cuenta → Cómo se construyen estas referencias →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

1.2K2 Sep

2.2K

1.1K3 Sep

891

9024 Sep

Last 6 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.09%2 Sep

0.27%

0.18%3 Sep

0.34%

1.92%

0.11%4 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 0.93%.

What the audience does

Likes78.6%11 in total

Replies14.3%2 in total

Quotes7.1%1 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Últimas publicaciones

Frente a cuentas del mismo tamaño

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Cuentas similares